I think you have an extra 0 in your number of patients.
How was the target price of $18 derived?
PE = 10x
No. of shares = 901M
At $18, Market cap = $16.2B
With $2B sales, net margin is expected to be 81%? Seems too high, even Sarepta with $1B of revenue is still making a loss...
Perhaps you meant PS of 10x?
Ann: Percheron Therapeutics Limited Corporate Presentation, page-6
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.4¢ |
Change
-0.001(1.33%) |
Mkt cap ! $66.71M | |||
| Open | High | Low | Value | Volume |
| 7.5¢ | 7.5¢ | 7.2¢ | $49.57K | 678.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55000 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.6¢ | 141155 | 2 |
View Market Depth
| Last trade - 14.44pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
-0.001 ( 5.26 %) |
||||
| Open | High | Low | Volume | ||
| 7.3¢ | 7.4¢ | 7.2¢ | 151427 | ||
| Last updated 14.47pm 30/05/2024 ? | |||||
| PER (ASX) Chart |